NCT03841617 2026-02-17
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT04447183 2023-10-23
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Unknown
NCT03244956 2021-09-28
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown